Comparative characteristics of major international and national guidelines for the treatment of chronic hepatitis B


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The mainstay of treatment for chronic hepatitis B (CHB) is to improve the quality of life and its duration, by preventing disease progression to cirrhosis, decompensated cirrhosis, end-stage liver disease, hepatocellular carcinoma, and death. By 2015, pegylated interferons and six nucleoside analogues may be used to treat CHB. The article provides comparative characteristics of major international and Russian guidelines for the selection of patients with CHB for antiviral therapy and compares a treatment policy for this category of patients.

Full Text

Restricted Access

About the authors

O. S Efremova

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: ks517@yandex.ru

O. G Yurin

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: oleg_gerald@mail.ru

References

  1. WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva Switzerlend: World Health Organization. May 12, 2015.
  2. Ивашкин В.Т. Лечение и профилактика хронического гепатита В в России. Российские медицинские вести 2010; XV(1): 65-70.
  3. Рекомендации по диспансерному наблюдению и лечению больных хроническим вирусным гепатитом В. Материалы I Ежегодного Всероссийского Конгресса по инфекционным болезням. М., 2009. 51 с.
  4. Liaw Y.F., Chu C.M. Hepatitis В virus infection. Lancet 2009; 373: 582-592.
  5. Papatheodoridis G.V., Manolakopoulos S., Dusheiko G., Archimandritis A.J. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis. 2008; 8(3): 167-178.
  6. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003; 23: 47-58.
  7. Hadziyannis S.J., Papatheodoridis G.V. Hepatitis Be antigen negative chronic hepatitis B - natural history and treatment. Semin Liver Dis. 2006; 26: 130-141.
  8. Абдурахманов Д.Т. HBeAg-негативный хронический гепатит В. Гепатологический форум 2006; 4: 4-7.
  9. Zarski J.P., Marcellin P., Leroy V., Trepo C., Samuel D., Ganne-Carrie N., Barange K., Canva V., Doffoel M., Cales P. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J. Viral. Hepatol. 2006; 45: 355-360.
  10. Funk M.L., Rosenberg D., Lok A. World-wide epidemiology of HBeAgnegative chronic hepatitis B and associated precore and core promoter variants. J. Viral. Hepatol. 2002; 9: 52-61.
  11. Ивашкин В.Т. Лечение и профилактика хронического гепатита В в России. Российские медицинские вести 2010; XV(1): 65-70.
  12. Ющук Н.Д., Знойко О.О., Климова Е.А., Дудина К.Р., Кареткина Г.Н., Ильина Е.Н., Максимов С.Л. Генетическая изменчивость вирусов гепатита человека и ее клиническое значение. М.: МГМСУ, 2007. 138 с.
  13. Kramvis A.A., Kew M.C. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to intivirl therapy. J. Viral. Hepatol. 2005; 12: 456-446.
  14. Bonino F., Marcellin P., Lau G., Hadziyannis S., Jin R., Piratvisuth T., Germanidis G., Yurdaydin C., Diago M., Gurel S., Lai M-Y., Brunetto M.R., Farci P., Popescu M., McCloud P. Predicting response to peginterferon a-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
  15. Flink H., van Zonneveld M., Hansen B. et al. HBV 99-01 Study Group. Treatment with peginterferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am. J. Gastroenterol. 2006; 101: 297-303.
  16. EASL Clinical Practice Guidelines. Management of chronic hepatitis B. J Hepatol. 2012; 57(1): 167-185.
  17. Lok A.S. 23.03.2009. 13th International Symposium on viral hepatitis and liver diseases. http://congress-ph.ru/common/ htdocs/upload/fm/gepatology/ 2014/1-4-2-rus.pdf
  18. Ивашкин В.Т., Ющук Н.Д., Маевская М.В., Знойко О.О., Дудина К.Р., Кареткина Г.Н., Климова Е.А., Максимов С.Л., Мартынов Ю.В., Маев И.В., Павлов Ч.С., Федосьин Е.А., Буеверов А.О., Абдурахманов Д.Т., Малышев Н.А., Никитин И.Г., Мойсюк Я.Г., Лапина Т.Л., Трухманов А.С., Кожевникова Г.М., Жданов К.В., Рахманова А.Г., Чуланов В.П., Шахгильдян И.В., Сюткин В.Е., Богомолов П.О. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению взрослых больных гепатитом В. Рос. журн. гастроэнтерол, гепатол, колопроктол. 2014; 3: 58-68.
  19. Terrault N.A., Bzowej N.H. AASLD guigelines for treatment of chronic hepatitis B: 2015. Hepatology 2015; 50(3): 2-23.
  20. EASL Clinical Practice Guidelines. Management of chronic hepatitis B. J. Hepatol. 2009; 50(2): 227-242.
  21. Marcellin P., Lau G., Bonino F., Farci P., Hadziyannis S, Jin R., Lu Z.M., Piratvisuth T., Germanidis G., Yurdaydin C., Diago M., Gure S., Lai M.Y., Button P., Pluck N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004; 351: 1206-1217.
  22. Weinbaum C., Williams I., Mast E., Wang S., Finelli L., Wasley A., Neitzel S., Ward J. Centers for Disease Control an Prevention (CDC) (2008) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 2008; 57 (RR-08): 2-20.
  23. Lok A.S.F., McMahon B.J. AASLD practice guidelines - Tronic hepatitis B. Hepatology 2007; 45: 507-539.
  24. Lau G.K., Piratvisuth T., Luo K.X. , Marcellin P., Thongsawat S., Cooksley G., Gane E., Fried M.W., Chow W.C., Paik S.W., Chang W.Y., Berg T., Flisiak R., McCloud P., Pluck N. Peginterferon àlfa-2a, lamivudini, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2682-2695.
  25. Lau G.K., Piratvisuth T., Luo K.X. Durability of response and occurrence of late response to peginterferon a-2a (40KD) (PEGASYS) one year post-treatment in patients with HBeAg-positive chronic hepatitis B. J. Hepatol. 2006; 44(Suppl 2): 2-300.
  26. Robinson W.S. The role of hepatitis B in the development of primary hepatocellular carcinoma: part I. J. Gastroenterol. Hepatol. 1992; 7(6): 622-638.
  27. Buster E.H., Flink H.J., Cakaloglu Y., Simon K., Trojan J., Nabak F., So T., Feinman S.V., Mach T., Akarca U.S., Schitten M., Tielemans W., van Vuuren A.J., Hansen B.E., Janssen H.L.A. Sustained HBeAg and HBsAg loss after long-term followup of HBeAg-positive patients treated with peginterferon alpha-2b AASLD2007. Poster 9.
  28. Marcellin P., Piratvisuth T., Brunetto M., Bonino F., Lau G.K.K., Farci P. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) with or without lamivudine: results four year follow-up. J. Hepatol. 2008; 48(2): 103 (Abstract).
  29. Soriano V., ed. HIV and viral hepatitis coinfection 2007. AIDS 2007; 21: 1073-1089.
  30. Soriano V., Puoti M., Bonacini M., Brook G., Cargnel A., Rockstroh J., Thio C., Benhamou Y. Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an HIV-HBV international panel. AIDS 2005; 19(3): 221-240.
  31. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2001; 34: 1225-1241.
  32. Moucari R., Mackiewicz V., Lada O., Ripault MP., Castelnau C., Martinot-Peignoux M., Dauvergne A., Asselah T., Boyer N., Bedossa P., Valla D., Vidaud M., Nicolas-Chanoine M.H., Marcellin P. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49(4): 1151-1157.
  33. Papatheodoridis G.V. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. J. Liver Int. 2011; 31(l): 95-103.
  34. Tenney D.J., Rose R.E., Baldick C.J., Pokornowski K.A., Eggers B.J., Fang J., Wichroski M.J., Xu D., Yang J., Wilber R.B., Colonno R.J. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenanve patients is rare through 5 years of therapy. Hepatology 2009; 49(5): 1503-1514.
  35. Kitrinos K.M., Corsa А., Liu У., Flaherty J., Snow-Lampart A., Marcellin P., Borroto-Esoda K., Miller M.D. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatolog. 2013; Aug 12. doi: 10.1002/hep.26686.
  36. Ide T., Kumashiro R., Kuwahara R., Koga H. Hepatitis B study group. Clinical course of patients with chronic hepatitis B with viral breakthrough during long-term lamivudine treatment. J. Gastroenterol. 2005; 40(6): 625-630.
  37. Liaw Y.F., Gane E., Leung N., Zeuzem S., Wang Y., Lai C.L., Heathcote E.J., Manns M., Bzowej N., Niu J., Han S.H., Hwang S.G, Cakaloglu Y., Tong M.J., Papatheodoridis G., Chen Y., Brown N.A., Albanis E., Galil K., Naoumov N.V. GLOBE Study Group. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136(2): 486-495.
  38. Guidelines for the Clinical Management and Treatment of HIV-infected Adalts in Europe (version 6.0; October, 2011). Europian AIDS Clinical Society).
  39. Lee H.W., Lee H.J., Hwang J.S., Sohn J.H., Jang J.Y., Han K.J., Park J.Y., Kim do Y., Ahn S.H., Paik Y.H., Lee C.K., Lee K.S., Chon C.Y., Han K.H. Lamivudine maintenance beyond one year aft er HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010; 51: 415-421.
  40. Reijnders J.G., Perquin M.J., Zhang N., Bettina E.H., Harry L.A., Janssen М. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion inmost patients with chronic hepatitis B. Gastroenterology 2010; 139: 491-498.
  41. Van Nunen A.B., Hansen В.Е., Suh D.J., Löhr H.F., Chemello L., Fontaine H., Heathcote J., Song B.C., Janssen H.L., de Man R.A., Schalm S.W. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pre-treatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-424.
  42. Lok A., Trinh H., Carosi G., Akarca U., Gadano A, Habersetzer F., Sievert Р., Wong W., Lovegren M., Cohen D., Llamoso C. Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide naive patients with chronic hepatitis B: the BELOW study. Hepatology 2011; 54: 471A.
  43. Chang T.T., Lai C.L., Kew Y.S., Lee S.S., Coelho H.S., Carrilho F.J., Poordad F., Halota W., Horsmans Y., Tsai N., Zhang H., Tenney D.J., Tamez R., Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigenpositive chronic hepatitis B. Hepatology 2010; 51: 422-430.
  44. Marcellin P., Buti М., Gane E.J., Krastev Z., Flisiak R., Germanidis G., Washington M.K., Barnes C.N., Flaherty J.F., Bornstein J.D., McHutchison J.G., Heathcote E.J. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and signifi cant regression of histological fibrosis and cirrhosis. Hepatology 2011; 54: 1011A.
  45. Heathcote E.J., Marcellin Р., Buti М., Buti М., Gane E., De Man R.A., Krastev Z., Germanidis G., Lee S.S., Flisiak R., Kaita K., Manns M., Kotzev I., Tchernev K., Buggisch P., Weilert F., Kurdas O.O., Shiffman M.L., Trinh H., Gurel S., Snow-Lampart A., Borroto-Esoda K., Mondou E., Anderson J., Sorbel J., Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-143.
  46. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г., Шахгильдян В.И., Козырина Н.В., Буравцова В.В.,Нарсия Р.С., Покровская А.В., Ефремова О.С., Коннов В.В., Куимова О.А., Попова А.А., Хохлова О.Н., Воронин Е.Е., Афонина Л.Ю., Васильева И.А., Зимина Е.Н. Национальные рекомендации по диспансерному наблюдению и лечению больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2015; 6(приложение). 72 с.
  47. Клинический протокол для Европейского региона ВОЗ. Гепатит В и ВИЧ-инфекция: тактика ведения пациентов с коинфекцией. Обновленная версия, 2011.
  48. Benhamou Y., Bochet M., Thibault V., Di Martino V., Caumes E., Bricaire F., Opolon P., Katlama C., Poynard T. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-1306.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies